Early cancer detection often leads to less aggressive treatments, reduced recovery times and higher survival rates.

A blood-based test has acceptable accuracy for colorectal cancer detection but not for advanced precancerous lesions in an ...

Let’s make June a turning point where more people get screened, more cancers are caught early and fewer lives are lost.

A circulating tumor DNA (ctDNA) blood test demonstrated high sensitivity and specificity for colorectal cancer (CRC) detection in a large average-risk population, study finds.

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield blood test for colorectal cancer (CRC) screening has been named a winner of Fast Company’s 2025 ...

Freenome plans to complete all modules of its premarket approval submission in mid-2025.